Genetics of Treatment Outcomes in Major Depressive Disorder: Present and Future
2
조회
0
다운로드
6
인용
0
참고문헌
키워드
초록
Pharmacogenetic testing is a useful and increasingly widespread tool to assist in antidepressant prescription. More than ten antidepressants (including tricyclics, selective serotonin reuptake inhibitors and venlafaxine) have already genetic biomarkers of response/side effects in clinical guidelines and drug labels. These are represented by functional genetic variants in genes coding for cytochrome enzymes (CYP2D6 and CYP2C19). Depending on the predicted metabolic activity, guidelines provide recommendations on drug choice and dosing. Despite not conclusive, the current evidence suggests that testing can be useful in patients who did not respond or tolerate at least one previous pharmacotherapy. However, the current recommendations are based on pharmacokinetic genes only (CYP450 enzymes), while pharmacodynamic genes (modulating antidepressant mechanisms of action in the brain) are still being studied because of their greater complexity. This may be captured by polygenic risk scores, which reflect the cumulative contribution of many genetic variants to a trait, and they may provide future clinical applications of pharmacogenetics. A more extensive use of genotyping in clinical practice may lead to improvement in treatment outcomes thanks to personalized treatments, but possible ethical issues and disparities should be taken into account and prevented.
Abstract
Pharmacogenetic testing is a useful and increasingly widespread tool to assist in antidepressant prescription. More than ten antidepressants (including tricyclics, selective serotonin reuptake inhibitors and venlafaxine) have already genetic biomarkers of response/side effects in clinical guidelines and drug labels. These are represented by functional genetic variants in genes coding for cytochrome enzymes (CYP2D6 and CYP2C19). Depending on the predicted metabolic activity, guidelines provide recommendations on drug choice and dosing. Despite not conclusive, the current evidence suggests that testing can be useful in patients who did not respond or tolerate at least one previous pharmacotherapy. However, the current recommendations are based on pharmacokinetic genes only (CYP450 enzymes), while pharmacodynamic genes (modulating antidepressant mechanisms of action in the brain) are still being studied because of their greater complexity. This may be captured by polygenic risk scores, which reflect the cumulative contribution of many genetic variants to a trait, and they may provide future clinical applications of pharmacogenetics. A more extensive use of genotyping in clinical practice may lead to improvement in treatment outcomes thanks to personalized treatments, but possible ethical issues and disparities should be taken into account and prevented.
참고문헌 (45)
- "DNA sequencing costs: data" (2017)[URL]
- Thomas L, "Prevalence of treatment-resistant depression in primary care : cross-sectional data", Br J Gen Pract, 63, pp.e852~e858 (2013)
- Souery D, "Treatment resistant depression : methodological overview and operational criteria", Eur Neuropsychopharmacol, 9, pp.83~91 (1999)
- Mrazek DA, "A review of the clinical, economic, and societal burden of treatment-resistant depression : 1996-2013", Psychiatr Serv, 65, pp.977~987 (2014)
- Ho SC, "Barriers and facilitators of adherence to antidepressants among outpatients with major depressive disorder : a qualitative study", PLoS One, 12, pp.e0179290~ (2017)
- Zetin M, "Rational antidepressant selection : applying evidence-based medicine to complex real-world patients", Psychopharmacol Bull, 39, pp.38~104 (2006)
- "Drug labels and clinical guideline annotations" (2019)[URL]
- Fabbri C, "Pharmacogenetic tests to guide drug treatment in depression : comparison of the available testing kits and clinical trials", Prog Neuropsychopharmacol Biol Psychiatry, 86, pp.36~44 (2018)
- "Clinical Pharmacogenetics Implementation Consortium guidelines" (2019)[URL]
- "Dutch Pharmacogenetic Working Group guidelines" (2019)[URL]
- Porcelli S, "Genetic polymorphisms of cytochrome P450 enzymes and antidepressant metabolism", Expert Opin Drug Metab Toxicol, 7, pp.1101~1115 (2011)
- Perry PJ, "Tricyclic antidepressant con-centrations in plasma : an estimate of their sensitivity and specificity as a predictor of response", J Clin Psychopharmacol, 14, pp.230~240 (1994)
- Charlier C, "Venlafaxine : the relationship between dose, plasma concentration and clinical response in depressive patients", J Psychopharmacol, 16, pp.369~372 (2002)
- Florio V, "Escitalopram plasma levels and antidepressant response", Eur Neuropsychopharmacol, 27, pp.940~944 (2017)
- Fabbri C, "Effect of cytochrome CYP2C19 metabolizing activity on antidepressant response and side effects : Meta-analysis of data from genome-wide association studies", Eur Neuropsychopharmacol, 28, pp.945~954 (2018)
- "Genetic testing statement" (2019)[URL]
- Spina E, "Clinical applications of CYP genotyping in psychiatry", J Neural Transm(Vienna), 122, pp.5~28 (2015)
- Elliott LS, "Clinical impact of pharmacogenetic profiling with a clinical decision support tool in polypharmacy home health patients : A prospective pilot randomized controlled trial", PLoS One, 12, pp.e0170905~ (2017)
- Bradley P, "Improved efficacy with targeted pharmacogenetic-guided treatment of patients with depression and anxiety : a randomized clinical trial demonstrating clinical utility", J Psychiatr Res, 96, pp.100~107 (2018)
- Pérez V, "Efficacy of prospective pharmacogenetic testing in the treatment of major depressive disorder : results of a randomized, double-blind clinical trial", BMC Psychiatry, 17, pp.250~ (2017)
- Ajeet B. Singh, "Improved Antidepressant Remission in Major Depression via a Pharmacokinetic Pathway Polygene Pharmacogenetic Report", Clinical Psychopharmacology and Neuroscience, 13(2), pp.150~156 (2015), 대한정신약물학회
- Winner JG, "A prospective, randomized, double-blind study assessing the clinical impact of integrated pharmacogenomic testing for major depressive disorder", Discov Med, 16, pp.219~227 (2013)
- Greden JF, "Impact of pharmacogenomics on clinical outcomes in major depressive disorder in the GUIDED trial : a large, patient-and rater-blinded, randomized, controlled study", J Psychiatr Res, 111, pp.59~67 (2019)
- Bousman CA, "Pharmacogenetic tests and depressive symptom remission : a meta-analysis of randomized controlled trials", Pharmacogenomics, 20, pp.37~47 (2019)
- Verbelen M, "Cost-effectiveness of pharmacogenetic-guided treatment: are we there yet?", Pharmacogenomics J, 17, pp.395~402 (2017)
- Hornberger J, "Cost-effectiveness of combinatorial pharmacogenomic testing for treatment-resistant major depressive disorder patients", Am J Manag Care, 21, pp.e357~e365 (2015)
- Groessl EJ, "Cost-effectiveness of a pharmacogenetic test to guide treatment for major depressive disorder", J Manag Care Spec Pharm, 24, pp.726~734 (2018)
- Maciel A, "Estimating cost savings of pharmacogenetic testing for depression in real-world clinical settings", Neuropsychiatr Dis Treat, 14, pp.225~230 (2018)
- "Ubiquitous Pharmacogenomics (U-PGx)" (2019)[URL]
- Anderson JS, "Polygenic risk scoring and prediction of mental health outcomes", Curr Opin Psychol, 27, pp.77~81 (2019)
- Knowles JW, "Cardiovascular disease : the rise of the genetic risk score", PLoS Med, 15, pp.e1002546~ (2018)
- Läll K, "Personalized risk prediction for type 2 diabetes : the potential of genetic risk scores", Genet Med, 19, pp.322~329 (2017)
- "Schizophrenia polygenic risk score and 20-year course of illness in psychotic disorders" (2019)[URL]
- García-González J, "Pharmacogenetics of antidepressant response : a polygenic approach", Prog Neuropsychopharmacol Biol Psychiatry, 75, pp.128~134 (2017)
- Nosengo N, "Can you teach old drugs new tricks?", Nature, 534, pp.314~316 (2016)
- Gaspar HA, "Using genetic drug-target networks to develop new drug hypotheses for major depressive disorder", Transl Psychiatry, 9, pp.117~ (2019)
- Wilkinson ST, "A new generation of antidepressants : an update on the pharmaceutical pipeline for novel and rapid-acting therapeutics in mood disorders based on glutamate", GABA neurotransmitter systems, 2019, pp.24, 606~615
- "Gene-edited babies: no one has the moral warrant to go it alone" (2018)[URL]
- Bousman C, "Towards the integration of pharmacogenetics in psychiatry : a minimum, evidence-based genetic testing panel", Curr Opin Psychiatry, 32, pp.7~15 (2019)
- "Genes" (2019)[URL]
- Mills MC, "A scientometric review of genome-wide association studies", Commun Biol, 2, pp.9~ (2019)
- Manrai AK, "Genetic misdiagnoses and the potential for health disparities", N Engl J Med, 375, pp.655~665 (2016)
- Rahman T, "Misleading guidance from pharmacogenomic Testing", Am J Psychiatry, 174, pp.922~924 (2017)
- Alessandro Serretti, "The Present and Future of Precision Medicine in Psychiatry: Focus on Clinical Psychopharmacology of Antidepressants", Clinical Psychopharmacology and Neuroscience, 16(1), pp.1~6 (2018), 대한정신약물학회[DOI]
- Maron E, "Manifesto for an international digital mental health network", Digit Psychiatry, 2, pp.14~24 (2019)